Stay ahead of developments in federal and state health care law, regulation and transactions with timely, expert news and analysis.
Life sciences companies will get some clarity about how the U.S. must approve cheaper copies of biologic drugs after the Supreme Court Jan. 13 agreed to review an appeals court decision ( Sandoz, Inc. v. Amgen, Inc., U.S., No. 15-1039, 1/13/17 ).
The acting U.S. solicitor general had advised the court that the decision by the U.S. Court of Appeals for the Federal Circuit concerning Sandoz’s Zarxio (filgrastim-sndz), a biosimilar of Amgen’s chemotherapy-related biologic Neupogen (filgrastim), incorrectly provided a six-month delay before biosimilars can come to market ( 11 LSLR 01, 1/6/17 ). The acting solicitor general recommended the high court grant review. The court agreed in an order with no comment.
“The Supreme Court’s grant of both Sandoz’s petition and Amgen’s conditional cross-petition will perpetuate, at least for several more months, the uncertainty as to how future biosimilar litigations will proceed,” Sanya Sukduang of Finnegan, Henderson, Farabow, Garrett & Dunner LLP told Bloomberg BNA in a Dec. 13 e-mail,
“Given the Acting Solicitor General position, however, biosimilar applicants have hope that the Supreme Court will overturn the decision and allow them to provide notice of commercial marketing well in advance of receiving final regulatory approval,” he said.
The high court will hear arguments in April and could issue a decision by the end of June.
Biologics are used to treat such diseases as cancer and hepatitis C. A biosimilar is a biologic drug product that is highly similar to a Food and Drug Administration-approved biologic. The Biologics Price Competition and Innovation Act (BPCIA) provides an abbreviated approval pathway for biosimilars that partly relies on data submitted for FDA approval of the original biologic, also known as a reference product (RP).
The abbreviated pathway allows lower development costs for the biosimilar than for the RP. The cost to consumers for most biosimilars is expected to be at least 15 percent less than the RP.
In exchange for the ability to use the RP’s data, the BPCIA provides that the biosimilar applicant will give the RP sponsor its abbreviated biologics license application (aBLA) for the biosimilar and jointly develop with the RP sponsor a list of the sponsor’s patents that the biosimilar might infringe. This exchange has been called “the patent dance.”
The BPCIA also provides for the biosimilar applicant to give the RP sponsor a 180-day notice of the date that it intends to commercially market the biosimilar.
In its Amgen decision, the Federal Circuit held that the patent dance wasn’t mandatory, as Sandoz argued, and that the 180-day notice couldn’t be issued until the FDA approved the biosimilar, as Amgen argued ( 09 LSLR, 7/24/15 ).
Sandoz, which is part of Novartis, petitioned for certiorari, and Amgen cross-petitioned.
Attorneys contacted by Bloomberg BNA offered different perspectives on the impact of the court’s action on life sciences law and industry.
“While the Supreme Court’s ultimate decision on these issues will result in regulatory and litigation war-gaming by biosimilar applicants and reference product sponsors, the court’s decision will necessarily rest on fundamental basics of statutory interpretation,” Sukduang wrote.
“Both Sandoz and Amgen have pointed out the Federal Circuit’s seemingly contradictory interpretation of the term ‘shall’ in the aBLA disclosure provisions of §262( l)(2)(A) and 180-day notice of commercial marketing provision of §262( l)(8)(A), and it will be interesting to see whether the court will apply the same, or different meaning, to the same term contained in the same piece of legislation,” he said.
Nicholas K. Mitrokostas, a partner in Goodwin Procter LLP’s intellectual property litigation group, Boston, told Bloomberg BNA in a Dec. 13 e-mail that the court’s decision to grant review isn’t surprising given the acting attorney general’s recommendation. “The grant today gives the court time to consider the issues and hand down a decision by the end of its current term in June.”
“However the case comes out, everyone on both sides of the issue will welcome getting a definitive answer to these important questions relatively early in the history of the BPCIA,” he said.”
To contact the reporter on this story: John T. Aquino in Washington at email@example.com
To contact the editor responsible for this story: Randy Kubetin at RKubetin@bna.com
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)